Cover Image
市場調查報告書

乳癌治療藥市場 - 全球產業分析、規模、佔有率、成長、趨勢,及2015∼2023年的預測

Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 338034
出版日期 內容資訊 英文 88 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
乳癌治療藥市場 - 全球產業分析、規模、佔有率、成長、趨勢,及2015∼2023年的預測 Breast Cancer Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
出版日期: 2015年11月25日 內容資訊: 英文 88 Pages
簡介

本報告提供乳癌治療藥市場相關調查、市場趨勢與今後的預測、市場機會等,加上各地區趨勢,及進入的主要企業的簡介等彙整。

第1章 序論

第2章 摘要整理

第3章 市場概要

  • 市場定義和概要
  • 流行病學和高風險群組
  • 乳癌的診斷和種類
  • 其他乳癌治療方法
  • 市場趨勢
    • 促進要素
      • 高發病率
      • 人口統計轉移
      • 肥胖罹患率上升
      • 診斷篩檢計劃
      • 民間醫療保險計劃的增加
    • 阻礙要素
      • 學名藥:品牌藥的替代
      • 競爭激烈:價格下降
      • 由於藥物成本高造成獲取障礙
      • 社會健康保險的不足
      • 乳癌治療藥嚴重的副作用
      • 賦予女性的權力不足的國家
      • 新的醫學性選擇
    • 機會
      • 國內製藥公司成長可能性
      • 並用藥物治療方法
      • 技術進步與藥物認證的趨勢
      • 新的搭配診斷模式
      • 對三陰性的藥物治療
      • 對HER2乳癌的複合適應的人
  • 市場魅力度分析
  • 競爭環境

第4章 市場區隔

  • 概要
  • HER2抑制劑市場收益
  • 分裂抑制劑市場收益
  • 代謝拮抗劑市場收益
  • 芳香酶抑制劑市場收益
  • 荷爾蒙受體市場收益

第5章 各地區市場

  • 簡介
  • 全球乳癌治療藥市場收益
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第6章 建議

第7章 企業簡介

  • AstraZeneca plc
  • Eisai株式會社
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer, Inc.
  • Puma Biotechnology, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

This report on the breast cancer therapeutics market studies the current as well as future prospects of the market globally. The stakeholders of this report include pharmaceutical companies and intermediaries engaged in the new drug discovery, pipeline development of various breast cancer therapeutics as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global breast cancer therapeutics market with respect to the leading market segments in terms of geography.

The global breast cancer therapeutics market has been studied based on major drug class segments, and their regional as well as national markets. Based on drug class, the global market has been categorized into five major segments: HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormone receptors. The market for these segments and sub-segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments, considering 2014 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the breast cancer therapeutics market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is illustrated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market.

Geographically, the breast cancer therapeutics market has been segmented into five regions: North America (the U.S. and Canada), Europe (the U.K., Germany, and Rest of Europe), Asia Pacific (Japan, South Korea, and Rest of APAC), Latin America (Brazil and Rest of Latin America), and Middle East & Africa (MEA). Market revenue in terms of US$ Mn and CAGR % from 2015 to 2023 are provided for all the regions and countries, considering 2014 as the base year.

The recommendations section included in the report would assist existing market players in expanding their market shares and new pharmaceutical companies in establishing their presence in the global breast cancer market. The report also profiles leading and emerging new players in the breast cancer therapeutics market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AstraZeneca plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., Puma Biotechnology, Sanofi S.A., and Teva Pharmaceutical Industries Ltd.

The global breast cancer therapeutics market has been segmented as follows:

Global Breast Cancer Therapeutics Market, by Drug Class

  • Overview
  • Global HER2 Inhibitors Market Revenue, 2015-2023 (US$ Mn)
  • Herceptin (Trastuzumab)
  • Tykerb (Lapatinib)
  • Perjeta (Pertuzumab)
  • Kadcyla (Ado-trastuzumab emtansine)
  • Global Mitotic Inhibitors Market Revenue, 2015-2023 (US$ Mn)
  • Halaven (Eribulin)
  • Taxotere (Docetaxel)
  • Ixempra (Ixabepilone)
  • Global Anti-metabolites Market Revenue, 2015-2023 (US$ Mn)
  • Gemzar (Gemcitabine)
  • Global Aromatase Inhibitors Market Revenue, 2015-2023 (US$ Mn)
    • Femara (Leterozole)
    • Aromasin (Exemestane)
    • Arimidex (Anastrozole)
    • Ibrance (Palbociclib)
    • Afinitor (Everolimus)
  • Global Hormone Receptor Market Revenue, 2015-2023 (US$ Mn)
  • Zoladex
  • Faslodex
  • Fareston

Global Breast Cancer Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
  • Asia Pacific
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

  • 2.1. Global Breast Cancer Therapeutics: Market Snapshot
  • 2.2. Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
  • 2.3. Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023(Value %)

3. Global Breast Cancer Therapeutics Market - Market Overview

  • 3.1. Market Definition and Overview
  • 3.2. Epidemiology & High Risk Groups
  • 3.3. Diagnosis and Types of Breast Cancer
  • 3.4. Other Breast Cancer Therapies
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Higher Incidence Rate
      • 3.5.1.2. Demographic Transition
      • 3.5.1.3. Rising Prevalence Of Obesity
      • 3.5.1.4. Diagnostic Screening Programs
      • 3.5.1.5. Increase in Private Health Insurance Plans:
    • 3.5.2. Restraints
      • 3.5.2.1. Generic Drugs: Substitute Branded Drugs
      • 3.5.2.2. Intense Competition: Fall in Prices
      • 3.5.2.3. Access barriers due to high drug costs
      • 3.5.2.4. Absence of Social Health Insurance
      • 3.5.2.5. Serious Side Effects of Breast Cancer Therapeutics
      • 3.5.2.6. Countries Lacking Women Empowerment
      • 3.5.3.7. Newer medication options
    • 3.5.3. Opportunities
      • 3.5.3.1. Potential Growth of Domestic Pharmaceutical Companies
      • 3.5.3.2. Combination Drug Therapy
      • 3.5.3.3. Technological Advancements and Robust Trends of Drug Approval
      • 3.5.3.4. New Companion Diagnostics Models
      • 3.5.3.5. Drug Therapy for Triple Negative(TNBC)
      • 3.5.3.6. Approval for Multiple Indications(positive & negative types) HER2 breast cancer
  • 3.7. Market Attractiveness Analysis- Breast Cancer Therapeutics Market, by Geography(2014)(%)
  • 3.8. Competitive Landscape - Breast Cancer Therapeutics Market, by Key Players, 2014(%)

4. Market Segmentation - By Drug Class

  • 4.1. Overview
  • 4.2. Global HER2 Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.2.1. Herceptin(Trastuzumab)
    • 4.2.2. Tykerb(Lapatinib)
    • 4.2.3. Perjeta(Pertuzumab)
    • 4.2.4. Kadcyla(Ado-trastuzumab emtansine)
  • 4.3. Global Mitotic Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.3.1. Halaven(Eribulin)
    • 4.3.2. Taxotere(Docetaxel)
    • 4.3.3. Ixempra(Ixabepilone)
  • 4.4. Global Anti-metabolites Market Revenue, 2015-2023(US$ Mn)
    • 4.4.1. Gemzar(Gemcitabine)
  • 4.5. Global Aromatase Inhibitors Market Revenue, 2015-2023(US$ Mn)
    • 4.5.1. Femara(Leterozole)
    • 4.5.2. Aromasin(Exemestane)
    • 4.5.3. Arimidex(Anastrozole)
    • 4.5.4. Ibrance(Palbociclib)
    • 4.5.5. Afinitor(Everolimus)
  • 4.6. Global Hormone Receptor Market Revenue, 2015-2023(US$ Mn)
    • 4.6.1. Zoladex
    • 4.6.2. Faslodex
    • 4.6.3. Fareston

5. Market Segmentation - By Geography

  • 5.1. Introduction
  • 5.2. Global Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
  • 5.3. North America Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.3.1. U.S.
    • 5.3.2. Canada
  • 5.4. Europe Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.4.1. Germany
    • 5.4.3. U.K.
    • 5.4.4. Rest of Europe
  • 5.5. Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015-2023(US$ Mn)
    • 5.5.1. Japan
    • 5.5.2. South Korea
    • 5.5.3. Rest of Asia Pacific
  • 5.6. Rest of the World
    • 5.6.1. Latin America
      • 5.6.1.1. Brazil
      • 5.6.1.2. Rest of Latin America
    • 5.6.2. Middle East and Africa

6. Recommendations

7. Company Profiles

  • 7.1. AstraZeneca plc
  • 7.2. Eisai Co., Ltd.
  • 7.3. Eli Lilly and Company
  • 7.4. F. Hoffmann-La Roche Ltd.
  • 7.5. GlaxoSmithKline plc
  • 7.6. Novartis International AG
  • 7.7. Pfizer, Inc.
  • 7.8. Puma Biotechnology, Inc.
  • 7.9. Sanofi S.A.
  • 7.10. Teva Pharmaceutical Industries Ltd.
Back to Top